ACR-368, a CHK1/2 Kinase Inhibitor, in Patients With Relapsed or Refractory Desmoplastic Small Round Cell Tumor: Phase I/II Trial Results Patients diagnosed with hereditary RC are more prone to ...

Patient-reported outcome measures improve survival risk and quality of life for cancer patients, according to a study published Aug. 13 in JAMA Network Open. PROMs are self-reported statements from ...

Providing the best patient-centered care, as measured by the individual patient's perceived value of care at a reasonable cost, has become the established definition of value-based health care (VBHC).

Historically, patient-reported outcome measures were primarily utilized for research purposes in orthopedics.However, renewed ...

A new policy review published in The Lancet Oncology and led by Ian Tannock and Madeline Pe, together with an international team of oncologists, statisticians, patients and patient-reported outcomes ...

Patient-reported outcome measures (PROMs) are crucial tools for assessing the health and well-being of children, yet their application in pediatrics faces unique challenges due to developmental ...

Forbes contributors publish independent expert analyses and insights. Michael L. Millenson writes about healthcare as a skeptical optimist. An unusual study gives a new twist to the idea of ...

To say “no” would be to ignore the fact that we have been collecting patient-reported outcome measures for more than 10 years. This effort began in orthopedics as a small pilot project at my ...

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

A multisociety taskforce has created a method for standardizing how patient outcomes are reported for heart valve disease (HVD), regardless of which valve is being treated and how. The objectives, the ...

Analysis of the phase 3 explorer7 (NCT04083781) study indicates a preference for concizumab prophylaxis over no prophylaxis in patients with hemophilia A or B with inhibitors. Among individuals with ...